Galectin Therapeutics Inc. Forecasted to Earn Q4 2017 Earnings of ($0.12) Per Share (GALT)
Galectin Therapeutics Inc. (NASDAQ:GALT) – Equities research analysts at Seaport Global Securities boosted their Q4 2017 EPS estimates for shares of Galectin Therapeutics in a research note issued to investors on Wednesday. Seaport Global Securities analyst V. Bernardino now forecasts that the company will earn ($0.12) per share for the quarter, up from their prior estimate of ($0.13). Seaport Global Securities currently has a “Buy” rating and a $5.00 target price on the stock. Seaport Global Securities also issued estimates for Galectin Therapeutics’ FY2019 earnings at ($0.50) EPS, FY2020 earnings at ($0.32) EPS and FY2021 earnings at ($0.18) EPS.
GALT has been the subject of several other reports. Zacks Investment Research downgraded Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. ValuEngine raised shares of Galectin Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 28th. Finally, Roth Capital began coverage on shares of Galectin Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $4.63.
Galectin Therapeutics (NASDAQ GALT) opened at $2.66 on Friday. Galectin Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.68.
Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.02.
Institutional investors have recently made changes to their positions in the stock. KCG Holdings Inc. boosted its position in Galectin Therapeutics by 1.9% during the 1st quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock worth $198,000 after purchasing an additional 1,592 shares during the period. Virtu KCG Holdings LLC boosted its position in Galectin Therapeutics by 24.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after purchasing an additional 21,008 shares during the period. Advisor Group Inc. boosted its position in Galectin Therapeutics by 10.4% during the 2nd quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock worth $1,191,000 after purchasing an additional 45,700 shares during the period. Vanguard Group Inc. boosted its position in Galectin Therapeutics by 18.2% during the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after purchasing an additional 134,165 shares during the period. Finally, Northern Trust Corp boosted its position in Galectin Therapeutics by 4.4% during the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after purchasing an additional 3,176 shares during the period. 9.93% of the stock is owned by hedge funds and other institutional investors.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.